April 27 (Reuters) – Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
“Rhapsido is the first oral targeted treatment approved for CSU, offering a unique approach to CSU treatment in a pill taken twice daily without any lab monitoring required,” the company said in a statement.
(Reporting by Amir Orusov, Editing by Friederike Heine)
Comments